4/4
05:39 pm
advm
Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight [Yahoo! Finance]
4/4
11:39 am
advm
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? [Yahoo! Finance]
3/27
11:20 am
advm
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) [Yahoo! Finance]
Low
Report
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) [Yahoo! Finance]
3/22
02:04 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/19
02:24 pm
advm
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies [Yahoo! Finance]
Low
Report
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies [Yahoo! Finance]
3/19
11:00 am
advm
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
3/19
09:00 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
3/19
08:37 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $3.00 to $2.00. They now have a "sector perform" rating on the stock.
3/18
04:20 pm
advm
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates [Yahoo! Finance]
Medium
Report
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates [Yahoo! Finance]
3/18
04:05 pm
advm
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Medium
Report
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
3/14
02:03 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/6
11:04 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/28
04:05 pm
advm
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
Medium
Report
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
2/12
08:00 am
advm
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Medium
Report
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/8
07:19 am
advm
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD [Yahoo! Finance]
High
Report
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD [Yahoo! Finance]
2/8
07:00 am
advm
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
High
Report
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
2/6
02:32 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target raised by analysts at Mizuho from $2.00 to $4.00. They now have a "buy" rating on the stock.
High
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target raised by analysts at Mizuho from $2.00 to $4.00. They now have a "buy" rating on the stock.
2/6
09:31 am
advm
Thinking about buying stock in Gorilla Technology, Li Auto, Osisko Mining, Adverum Biotechnologies, or Kingsoft Cloud?
High
Report
Thinking about buying stock in Gorilla Technology, Li Auto, Osisko Mining, Adverum Biotechnologies, or Kingsoft Cloud?
2/5
08:05 am
advm
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing [Yahoo! Finance]
High
Report
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing [Yahoo! Finance]
2/5
07:45 am
advm
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
High
Report
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
2/1
05:42 pm
advm
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 [Yahoo! Finance]
High
Report
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 [Yahoo! Finance]
2/1
05:30 pm
advm
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
High
Report
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
1/29
08:09 am
advm
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer [Yahoo! Finance]
Medium
Report
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer [Yahoo! Finance]
1/29
08:00 am
advm
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
Medium
Report
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer